Published: December 31, 2014

JBS Publication Demonstrates Utility of InSphero 3D Co-culture Microtissues as Phenotypic RNAi Screening Tool

JBS Publication Demonstrates Utility of InSphero 3D Co-culture Microtissues as Phenotypic RNAi Screening Tool

Schlieren, Switzerland, February 27, 2014 – Report in the Journal of Biomolecular Screening establishes a fluorescent 3D tumor co-culture model, enabling screening of gene function in a system more reflective of in vivo tumor growth. 

Research in the Journal of Biomolecular Screening, co-authored by InSphero AG and the Institute of Molecular Health Sciences (Zurich), characterizes a high-throughput compatible 3D tumor model system based on InSphero’s GravityPLUS™ hanging drop technology. The authors use the co-culture model and RNA interference (RNAi) to reveal differential phenotypic responses to targeted gene disruption that are dependent upon the 2D or 3D manner in which the cells are grown.

Currently, identification of drug targets and primary target validation are typically performed using 2D cell culture systems. These conditions do not reflect the interactive 3D tumor microenvironment in vivo. The study directly compares 2D and 3D co-culture microtissues composed of human DLD I colon cancer cells and murine fibroblasts, each genetically modified to allow simple quantification of tumor and fibroblast cell number by fluorescence imaging. Upon siRNA-mediated depletion of Kifl I/Eg5, a critical mitotic protein, cancer cell proliferation in 3D microtissues was inhibited, whereas those in 2D monolayers were more resistant to gene depletion and continued to proliferate.

Dr. Jens M. Kelm, Chief Scientific Officer at InSphero AG and corresponding author on the manuscript, states the 3D co-culture model attempts to more accurately reflect the heterotypic interactions seen in vivo, while also being amenable to high-throughput approaches to early target identification and validation. “Our findings reiterate the importance of the cellular context in which gene function analysis studies are performed. Co-cultures grown in 3D may display a dramatically different result in phenotypic screens than in traditional 2D monolayers.”

InSphero provides a broad portfolio of assay-ready 3D InSight™ Tumor Microtissues from widely used cell lines, including various co-cultures with human or mouse stromal cells, and Fluorescent Microtissues expressing reporters to distinguish tumor and stromal cell populations.

To find out more about InSphero, browse our website.

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource